Skip to content
HowShorted

Coherus Oncology, Inc. short interest in 2022

In 2022, Coherus Oncology, Inc.'s disclosed short interest ran from 8.94% of shares outstanding on 14 Jan 2022 to 12.80% on 30 Dec 2022, a change of +3.86 percentage points. The year's high was 14.19% on 30 Jun 2022 and its low 8.51% on 31 Jan 2022, averaging 11.71% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.97 days on 30 Nov 2022. Full history: Coherus Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Coherus Oncology, Inc. in 2022

2022 in figures

Start of year
8.94% (14 Jan 2022)
End of year
12.80% (30 Dec 2022)
Change
+3.86 pp
High
14.19% (30 Jun 2022)
Low
8.51% (31 Jan 2022)
Average
11.71%
Highest days to cover
12.97 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

Coherus Oncology, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.94%7.69
31 Jan 20228.51%6.73
15 Feb 20229.69%7.31
28 Feb 20229.19%7.06results (8-K), 10-K filed
15 Mar 20229.07%11.27
31 Mar 20229.88%8.72
14 Apr 20229.90%10.46
29 Apr 202211.25%10.54
13 May 202213.06%7.6510-Q filed, results (8-K)
31 May 202213.16%8.96
15 Jun 202212.56%10.87
30 Jun 202214.19%8.48
15 Jul 202212.72%10.53
29 Jul 202213.67%10.80
15 Aug 202213.39%7.1910-Q filed, results (8-K)
31 Aug 202212.24%11.09
15 Sep 202212.10%7.07
30 Sep 202212.37%9.10
14 Oct 202211.96%10.50
31 Oct 202211.98%10.50
15 Nov 202212.83%7.3210-Q filed, results (8-K)
30 Nov 202213.02%12.97
15 Dec 202212.45%11.64
30 Dec 202212.80%4.77

See also: Coherus Oncology, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.